SCHEMBL280026

SCHEMBL280026

Cc1ccc(C(=O)N(C)CCC(=O)O)s1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
POLB P06746 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
DAO P14920 1/20 0.50
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
TAS1R3 Q7RTX0 1/20 0.41
TAS1R1 Q7RTX1 1/20 0.41
ALDH1A1 P00352 3/20 0.41
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
USP2 O75604 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
NPSR1 Q6W5P4 3/20 0.40
CHEK1 O14757 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL279686 0.83 DAO (0.53) KMT2APOLBTDP1DAOTAS1R3
SCHEMBL14174956 0.83 DAO (0.48) KMT2APOLBTDP1DAOTAS1R3
SCHEMBL16313560 0.83 DAO (0.44) KMT2APOLBTDP1DAOTAS1R3
SCHEMBL12313821 0.81 POLB (0.43) KMT2APOLBTDP1ITGB3ITGA2B
SCHEMBL12265898 0.80 RXFP1 (0.43) KMT2ADAOITGB3ITGA2BNPC1
SCHEMBL14395496 0.80 ITGB3 (0.40) ITGB3ITGA2BALDH1A1SMN1; SMN2CHEK1
SCHEMBL328097 0.80 DAO (0.52) KMT2APOLBTDP1DAOTAS1R3
SCHEMBL12121243 0.75 DAO (0.47) KMT2APOLBTDP1DAOTAS1R3
SCHEMBL327978 0.75 DAO (0.47) KMT2APOLBTDP1DAOTAS1R3
SCHEMBL11203075 0.75 DAO (0.59) KMT2APOLBTDP1DAOTAS1R3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL KMT2A 3398/4885POLB 4352/4885TDP1 2969/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.